Hercules Capital, Inc. (HTGC)
Chart Events
Performance Outlook
| Previous Close | 15.13 |
| Open | 15.24 |
| Bid | 15.47 x 800 |
| Ask | 15.48 x 1400 |
| Day's Range | 15.19 - 15.52 |
| 52 Week Range | 12.62 - 19.09 |
| Volume | |
| Avg. Volume | 1,402,038 |
| Market Cap | 1.792B |
| Beta (5Y Monthly) | 1.31 |
| PE Ratio (TTM) | 5.58 |
| EPS (TTM) | 2.77 |
| Earnings Date | Apr 27, 2022 - May 02, 2022 |
| Forward Dividend & Yield | 1.40 (8.80%) |
| Ex-Dividend Date | Aug 08, 2022 |
| 1y Target Est | 17.39 |
- Zacks
Robust Loan Originations Aid Hercules Capital (HTGC) Top Line
Driven by the growing demand for customized financing, Hercules Capital's (HTGC) top line is expected to keep improving.
- Motley Fool
Axsome Therapeutics (AXSM) Q2 2022 Earnings Call Transcript
Image source: The Motley Fool. Axsome Therapeutics (NASDAQ: AXSM)Q2 2022 Earnings CallAug 09, 2022, 8:00 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood morning, and welcome to the Axsome Therapeutics conference call.
- GlobeNewswire
Gritstone Reports Second Quarter 2022 Financial Results and Provides Business Update
-- Clinical programs continue to progress, with initial data from Phase 2 study of “off the shelf” SLATE-KRAS and multiple studies within T cell-enhanced SARS-CoV-2 program (CORAL) expected this year -- -- Follow up data from subset of CORAL-BOOST study shows strong neutralizing antibody titers persisted without decay for at least 6 months after single boost administration of self-amplifying mRNA (samRNA) -- -- New credit facility provides financial flexibility entering period of multiple potent
- Xilio Therapeutics Announces Encouraging Preliminary Phase 1 Dose-Escalation Data for XTX101, a Tumor-Selective Anti-CTLA-4, and Reports Pipeline and Business Updates and Second Quarter 2022 Financial ResultsGlobeNewswire
- SI-BONE, Inc. Reports Financial Results for the Second Quarter 2022GlobeNewswire
